Cannabis News

48north stock

Ayurcann

Toll Processing & White Label Solutions for Licensed Producers

AYUR:CNX
CSE:AYUR


Overview

In an industry that was previously reliant on grower companies, more fully integrated companies delivering multiple verticals in cannabis processing and production offer an unparalleled investment opportunity that stands out from the rest.

Ayurcann (CSE:AYUR) is a leading B2B post-harvest solution and provider focused on providing scalable custom processes and pharma-grade products to the medical cannabis industry in Canada. Ayurcann is focused on becoming the partner of choice for leading Canadian cannabis brands by delivering best-in-class, proprietary services, including ethanol extraction, formulation, product development and custom manufacturing.

The company offers a two-tier business model of services and production. The manufacturing vertical offers three production divisions specializing in expert cannabis-based extraction and refinement, high-quality bulk oil sales and white label manufacturing. Ayurcann currently extracting approximately 1,500 kilograms a week of product and has the capacity to process up to 200,000 kilograms of dry cannabis annually.

Additionally, its proprietary Ayurcann Marketplace offers a premium selection of cannabis and hemp products, including tinctures, vapes and topicals for personalized care.

The company operates out of Pickering, Ontario, allowing Ayurcann to leverage easy access to licensed producers and other cannabis participants in the region. It also holds Processing and Research Licences issued by Health Canada.

Ayurcann’s management team consists of innovators in the cannabis and corporate space that bring together years of experience in business development, finance, post-harvest production and quality control. This leadership and their vested interest in the success of

Company Highlights

  • Ayurcann is a premier post-harvest cannabis solutions company focused on providing and manufacturing unique development processes and high-quality products for patient and adult use in Canada.
  • The company aims to be a market leader and supportive partner within the cannabis extraction business. It has created turn-key-post harvest outsourcing for licensed cannabis producers, using a strategic end-to-end model.
  • The company’s Ayurcann Solutions offers premium services across various cannabis production verticals. This portfolio includes expert cannabis-based extraction and refinement, high-quality bulk oil sales and white label manufacturing.
  • Ayurcann also operates the Ayurcann Marketplace, specializing in safe and well-engineered medicinal cannabis concentrate products for personalized and patient care.

Get access to more exclusive Cannabis Investing Stock profiles here

Recent News

Company News

Avicanna's Subsidiary Santa Marta Golden Hemp Completes First Commercial Export of Feminized Cannabis Seeds to Lesotho

Avicanna Inc. a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products is pleased to announce that, through its majority owned Colombian subsidiary, Santa Marta Golden Hemp S.A.S. the Company has completed its first commercial export of feminized cannabis seeds to the African region with an initial export to Lesotho. The development, ...

This export marks the 16 th international market entry for Avicanna and the first export of proprietary genetics into Africa.

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

New Survey Shows Majority of Cannabis Consumption is Attributable to Consumers' Desires to Address Health and Wellness Concerns

62% of Americans Would Prefer Cannabis Over Pharmaceuticals When Treating a Medical Issue A new survey conducted by The Harris Poll on behalf of Curaleaf Holdings, Inc. a leading international provider of consumer products in cannabis, finds that 91% of adults aged 21+ who have ever consumed cannabis have done so for health and wellness purposes. The findings offer important takeaways revealing people's attitudes ...

62% of Americans Would Prefer Cannabis Over Pharmaceuticals When Treating a Medical Issue

A new survey conducted by The Harris Poll on behalf of Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF) ("Curaleaf" or the "Company"), a leading international provider of consumer products in cannabis, finds that 91% of adults aged 21+ who have ever consumed cannabis have done so for health and wellness purposes. The findings offer important takeaways revealing people's attitudes toward both cannabis and the desire for holistic health and wellness, as 75% of Americans say they would prefer holistic solutions over pharmaceuticals to treat a medical issue when possible, with 62% of people saying they would prefer to use cannabis rather than pharmaceuticals to treat a medical issue.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Will Germany's Cannabis Actions Create a Domino Effect in Europe?

Experts think recreational cannabis legalization in Germany could pressure nearby countries to follow suit.

As Germany gears up to possibly legalize adult-use cannabis, how likely is it that the country's plans will cause other nations in Europe to follow suit?

The roadmap for recreational cannabis legalization in Germany has become a hot topic for stakeholders in the overall industry. On top of how exactly the situation will play out and what business opportunities exist, market watchers have offered various opinions on what the lasting impact of this change could be.

Keep reading...Show less

Cannabis Weekly Round-Up: US Reform Talk Cools Off, Analyst Says

Leading cannabis analyst Vivien Azer of Cowen said during the latest earnings season companies in the sector tempered discussions around US legalization.

A cannabis analyst for Cowen highlighted that companies in the sector are adjusting their messaging and expectations around federal reform in the US marketplace.

Meanwhile, Aurora Cannabis (NASDAQ:ACB,TSX:ACB) had a difficult trading week after a new investment deal.

Keep reading to find out more cannabis highlights from the past five days.

Keep reading...Show less